Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Opko Health Inc (OPK)
NASDAQ:OPK
Holding OPK?
Track your performance easily
OPK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.86 - $1.76
Previous CloseN/A
Volume574.71K
Average Volume (3M)3.11M
Market Cap
$1.01B
Enterprise Value$1.59B
Total Cash (Recent Filing)$168.73M
Total Debt (Recent Filing)$90.44M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Feb 20, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding682,483,030
10 Day Avg. Volume2,495,034
30 Day Avg. Volume3,105,794
Standard Deviation0.21
R-Squared0.17
Alpha0.00084
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.42
Price to Cash Flow (P/CF)1.80
P/FCF Ratio1.90
Enterprise Value/Market Cap1.58
Enterprise Value/Revenue2.24
Enterprise Value/Gross Profit5.01
Enterprise Value/Ebitda-12.57
Forecast
1Y Price Target
$2.75Price Target Upside80.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Opko Health News
PremiumCompany Announcements
Opko Health Engages Investors at J.P. Morgan Conference
PremiumCompany Announcements
OPKO Health Shows Strategic Progress in Q3 2024
Bulls Say, Bears Say
Bulls Say
Financial PerformanceNet income was $24.9M, or $0.03 per diluted share, beating our estimated loss of $66.5M due to $121.5M of gain on sale of assets.
Strategic PartnershipsModeX Therapeutics entered into an exclusive worldwide license and collaboration agreement with Merck for the development of MDX-2201—a preclinical nanoparticle vaccine candidate targeting the Epstein-Barr virus.
Vaccine DevelopmentMDX2201 has the potential to become the first EBV vaccine cleared for marketing in the U.S., addressing a virus with no current FDA-approved vaccine or treatment.
Bears Say
Revenue MissRevenue came in lower than estimated, with consolidated total revenues at $173.6M.
Revenue PerformanceOPKO's third quarter top-line performance was a bit light relative to expectations.
Year-over-Year DeclineConsolidated total revenues represented a 3% year-over-year decline.
---
Ownership Overview
51.34% Insiders
6.46% Mutual Funds
0.19% Other Institutional Investors
30.55% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OPK FAQ
What was Opko Health Inc’s price range in the past 12 months?
Opko Health Inc lowest stock price was $0.86 and its highest was $1.76 in the past 12 months.
What is Opko Health Inc’s market cap?
Opko Health Inc’s market cap is $1.01B.
When is Opko Health Inc’s upcoming earnings report date?
Opko Health Inc’s upcoming earnings report date is Feb 20, 2025 which is in 19 days.
How were Opko Health Inc’s earnings last quarter?
Opko Health Inc released its earnings results on Nov 07, 2024. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.093 by $0.123.
Is Opko Health Inc overvalued?
According to Wall Street analysts Opko Health Inc’s price is currently Undervalued.
Does Opko Health Inc pay dividends?
Opko Health Inc does not currently pay dividends.
What is Opko Health Inc’s EPS estimate?
Opko Health Inc’s EPS estimate is -0.09.
How many shares outstanding does Opko Health Inc have?
Opko Health Inc has 682,483,030 shares outstanding.
What happened to Opko Health Inc’s price movement after its last earnings report?
Opko Health Inc reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.093. Following the earnings report the stock price went up 4.828%.
Which hedge fund is a major shareholder of Opko Health Inc?
Among the largest hedge funds holding Opko Health Inc’s share is Gamco Investors, Inc. ET AL. It holds Opko Health Inc’s shares valued at 261K.
---
Opko Health Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.75 (80.92% Upside)
$2.75 (80.92% Upside)
Blogger Sentiment
Bullish
OPK Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 3.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.14%
12-Months-Change
Fundamentals
Return on Equity
-9.53%
Trailing 12-Months
Asset Growth
9.70%
Trailing 12-Months
Company Description
Opko Health Inc
OPKO Health, Inc. engages in the provision of healthcare services. It operates through the Diagnostics and Pharmaceuticals segments. The Diagnostics segment comprises clinical laboratory operations which acquired through the Bio-Reference and point-of-care operations. The Pharmaceuticals segment includes the pharmaceutical operations acquired in Chile, Mexico, Ireland, Israel, and Spain; and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.
---
OPK Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment, driven by strategic asset sales, strong growth in key diagnostics areas, and significant financial improvements. Despite some revenue declines in specific segments, the company's overall financial health and strategic partnerships indicate a strong position moving forward.Read More>---
OPK Stock 12 Month Forecast
Average Price Target
$2.75
▲(80.92% Upside)
Technical Analysis
Best Analysts Covering OPK
1 Year
1 Year Success Rate
16/38 ratings generated profit
1 Year Average Return
+10.17%
reiterated a buy rating 3 months ago
Copying Michael Petusky's trades and holding each position for 1 Year would result in 42.11% of your transactions generating a profit, with an average return of +10.17% per trade.
---